Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical ...

Crossmark Global Holdings Inc. lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free ...

Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by equities research analysts at William ...

Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and ...

Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

Abeona Therapeutics Inc.'s promising gene therapy for RDEB, potential FDA approval, undervalued stock, and key risks. Click ...

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence: ...

William Blair downgraded Charles River (CRL) to Market Perform from Outperform.Invest with Confidence: Follow TipRanks' Top Wall Street ...

T-cell immunotherapy company Atara Biotherapeutics closed 8% lower on Tuesday, having lost 41% of its stock market value on ...